Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

Abstract:

Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HPV vaccination coverage is low in the United States. Objectives:To estimate the prevalence of genital HPV infection and the HPV vaccination rate in the United States among adult men and to examine potential risk factors for HPV infection. Design, Setting, and Participants:The National Health and Nutrition Examination Survey (NHANES) samples a representative cross-section of the US population. Men aged 18 to 59 years were examined in mobile examination centers during the NHANES 2013-2014. DNA was extracted from self-collected penile swab specimens, and HPV genotyping was performed by polymerase chain reaction amplification. Demographic and vaccination information was gathered via self-report during home-based standardized interviews. Binary multivariable logistic regression was used to estimate the odds of HPV infection. Main Outcomes and Measures:The prevalence of genital HPV infection and the HPV vaccination coverage rate among adult men. Results:During the NHANES 2013-2014, a total of 1868 men aged 18 to 59 years were examined. The overall genital HPV infection prevalence was 45.2% (95% CI, 41.3%-49.3%). The infection prevalence with at least 1 high-risk HPV subtype defined by DNA testing was 25.1% (95% CI, 23.0%-27.3%). In vaccine-eligible men, the prevalence of infection with at least 1 HPV strain targeted by the HPV 4-valent vaccine and HPV 9-valent vaccine was 7.1% (95% CI, 5.1%-9.5%) and 15.4% (95% CI, 11.7%-19.6%), respectively. Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%). Conclusions and Relevance:Among men aged 18 to 59 years in the United States, the overall prevalence of genital HPV infection was 45.2% (95% CI, 41.3%-49.3%). The overall genital HPV infection prevalence appears to be widespread among all age groups of men, and the HPV vaccination coverage is low.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

doi

10.1001/jamaoncol.2016.6192

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

810-816

issue

6

eissn

2374-2437

issn

2374-2445

pii

2598492

journal_volume

3

pub_type

杂志文章
  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

    abstract:Importance:Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective:To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2016.3904

    authors: Melisko ME,Goldman ME,Hwang J,De Luca A,Fang S,Esserman LJ,Chien AJ,Park JW,Rugo HS

    更新日期:2017-03-01 00:00:00

  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care.

    abstract:Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4549

    authors: Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

    更新日期:2017-03-01 00:00:00

  • Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.

    abstract:IMPORTANCE:Contrary to practice guidelines, breast magnetic resonance imaging (MRI) is commonly used in the preoperative evaluation of women with breast cancer. While existing literature has found little benefit to MRI in most patients, potential downstream consequences associated with breast MRI are not well described...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3018

    authors: Arnaout A,Catley C,Booth CM,McInnes M,Graham I,Kumar V,Simos D,Van Walraven C,Clemons M

    更新日期:2015-12-01 00:00:00

  • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

    abstract:Importance:The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective:To compare 6 cycles of paclitaxel plus carboplatin (PCb) wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2965

    authors: Yu KD,Ye FG,He M,Fan L,Ma D,Mo M,Wu J,Liu GY,Di GH,Zeng XH,He PQ,Wu KJ,Hou YF,Wang J,Wang C,Zhuang ZG,Song CG,Lin XY,Toss A,Ricci F,Shen ZZ,Shao ZM

    更新日期:2020-09-01 00:00:00

  • Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

    abstract:Importance:Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2016.6120

    authors: Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R,Jukkola-Vuorinen A,Tanner M,Kokko R,Ahlgren J,Auvinen P,Lahdenperä O,Kosonen S,Villman K,Nyandoto P,Nilsson G,Poikonen-Saksela P,Kataja V,Junnila J,Bono P,Lindman H

    更新日期:2017-06-01 00:00:00

  • Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

    abstract:IMPORTANCE:Statin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for SLCO2B1, an organic anionic transporter. We previously demonstrated that genetic variants of SLCO2B1 correlated with time to progression (TTP) durin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.0829

    authors: Harshman LC,Wang X,Nakabayashi M,Xie W,Valenca L,Werner L,Yu Y,Kantoff AM,Sweeney CJ,Mucci LA,Pomerantz M,Lee GS,Kantoff PW

    更新日期:2015-07-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

    abstract:IMPORTANCE:Instituting widespread measurement of outcomes for cancer hospitals using administrative data is difficult owing to lack of cancer-specific information such as disease stage. OBJECTIVE:To evaluate the performance of hospitals that treat patients with cancer using Medicare data for outcome ascertainment and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3151

    authors: Pfister DG,Rubin DM,Elkin EB,Neill US,Duck E,Radzyner M,Bach PB

    更新日期:2015-12-01 00:00:00

  • Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

    abstract:Importance:The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective:To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer....

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2016.1197

    authors: Powles T,Sarwar N,Stockdale A,Sarker SJ,Boleti E,Protheroe A,Jones R,Chowdhury S,Peters J,Oades G,O'Brien T,Sullivan M,Aitchison M,Beltran L,Worth D,Smith K,Michel C,Trevisan G,Harvey-Jones E,Wimalasingham A,Sahde

    更新日期:2016-10-01 00:00:00

  • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

    abstract:IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.5941

    authors: Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

    更新日期:2016-06-01 00:00:00

  • Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

    abstract:Importance:Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed in patients with subclinical disease with advanced NSCLC, and no useful clinical biomar...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5860

    authors: Toi Y,Sugawara S,Sugisaka J,Ono H,Kawashima Y,Aiba T,Kawana S,Saito R,Aso M,Tsurumi K,Suzuki K,Shimizu H,Domeki Y,Terayama K,Nakamura A,Yamanda S,Kimura Y,Honda Y

    更新日期:2019-03-01 00:00:00

  • Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.

    abstract:Importance:Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. Objective:To examine the association of chemotherapy with survival in elderly patients with mult...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2388

    authors: Tamirisa N,Lin H,Shen Y,Shaitelman SF,Sri Karuturi M,Giordano SH,Babiera G,Bedrosian I

    更新日期:2020-10-01 00:00:00

  • Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.

    abstract:Importance:Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care for patients with small cell lung cancer. Data on SRS are limited. Objective:To characterize and compare first-line SRS outcomes (withou...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2020.1271

    authors: Rusthoven CG,Yamamoto M,Bernhardt D,Smith DE,Gao D,Serizawa T,Yomo S,Aiyama H,Higuchi Y,Shuto T,Akabane A,Sato Y,Niranjan A,Faramand AM,Lunsford LD,McInerney J,Tuanquin LC,Zacharia BE,Chiang V,Singh C,Yu JB,Brau

    更新日期:2020-07-01 00:00:00

  • Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

    abstract:Importance:Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patient...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0250

    authors: He M,Li Q,Zou R,Shen J,Fang W,Tan G,Zhou Y,Wu X,Xu L,Wei W,Le Y,Zhou Z,Zhao M,Guo Y,Guo R,Chen M,Shi M

    更新日期:2019-07-01 00:00:00

  • Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.

    abstract:IMPORTANCE:Multiple myeloma has been classified as exhibiting "limited or suggestive evidence" of an association with exposure to herbicides in Vietnam War veterans. Occupational studies have shown that other pesticides (ie, insecticides, herbicides, fungicides) are associated with excess risk of multiple myeloma and i...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.2938

    authors: Landgren O,Shim YK,Michalek J,Costello R,Burton D,Ketchum N,Calvo KR,Caporaso N,Raveche E,Middleton D,Marti G,Vogt RF Jr

    更新日期:2015-11-01 00:00:00

  • Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

    abstract:Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6065

    authors: Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

    更新日期:2016-05-01 00:00:00

  • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

    abstract:Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this diseas...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.0219

    authors: Frezza AM,Jones RL,Lo Vullo S,Asano N,Lucibello F,Ben-Ami E,Ratan R,Teterycz P,Boye K,Brahmi M,Palmerini E,Fedenko A,Vincenzi B,Brunello A,Desar IME,Benjamin RS,Blay JY,Broto JM,Casali PG,Gelderblom H,Grignani G,

    更新日期:2018-09-01 00:00:00

  • The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

    abstract:IMPORTANCE:Positive phase 3 cancer clinical trials are widely hailed, while trials with negative results are often interpreted as scientific failures. We hypothesized that these interpretations would be reflected in the scientific literature. OBJECTIVE:To compare the scientific impact of positive vs negative phase 3 c...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6487

    authors: Unger JM,Barlow WE,Ramsey SD,LeBlanc M,Blanke CD,Hershman DL

    更新日期:2016-07-01 00:00:00

  • Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

    abstract:Importance:Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associatio...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.3340

    authors: Gierach GL,Curtis RE,Pfeiffer RM,Mullooly M,Ntowe EA,Hoover RN,Nyante SJ,Feigelson HS,Glass AG,Berrington de Gonzalez A

    更新日期:2017-02-09 00:00:00

  • Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

    abstract:Importance:Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of therapy is unknown. ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.4060

    authors: Raut CP,Espat NJ,Maki RG,Araujo DM,Trent J,Williams TF,Purkayastha DD,DeMatteo RP

    更新日期:2018-12-01 00:00:00

  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

    abstract:Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6380

    authors: Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

    更新日期:2017-07-01 00:00:00

  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

    abstract:Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susce...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2054

    authors: Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

    更新日期:2016-10-01 00:00:00

  • Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.

    abstract:Importance:Although adjuvant endocrine therapy confers a survival benefit among females with hormone receptor (HR)-positive breast cancer, the effectiveness of this treatment among males with HR-positive breast cancer has not been rigorously investigated. Objective:To investigate trends, patterns of use, and effective...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1114

    authors: Venigalla S,Carmona R,Guttmann DM,Jain V,Freedman GM,Clark AS,Shabason JE

    更新日期:2018-10-01 00:00:00

  • Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

    abstract:Importance:A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. Objective:To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endo...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.4794

    authors: Sparano JA,Gray RJ,Makower DF,Albain KS,Saphner TJ,Badve SS,Wagner LI,Kaklamani VG,Keane MM,Gomez HL,Reddy PS,Goggins TF,Mayer IA,Toppmeyer DL,Brufsky AM,Goetz MP,Berenberg JL,Mahalcioiu C,Desbiens C,Hayes DF,Dees

    更新日期:2020-03-01 00:00:00

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

    abstract:Importance:Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives:To i...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.3676

    authors: Ferrara R,Mezquita L,Texier M,Lahmar J,Audigier-Valette C,Tessonnier L,Mazieres J,Zalcman G,Brosseau S,Le Moulec S,Leroy L,Duchemann B,Lefebvre C,Veillon R,Westeel V,Koscielny S,Champiat S,Ferté C,Planchard D,Remon

    更新日期:2018-11-01 00:00:00

  • Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.

    abstract:Importance:Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compar...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.0997

    authors: Jalali R,Gupta T,Goda JS,Goswami S,Shah N,Dutta D,Krishna U,Deodhar J,Menon P,Kannan S,Sarin R

    更新日期:2017-10-01 00:00:00

  • Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.

    abstract:Importance:Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC). Objective:To explore milestone rate, a proposed intermediate end point for immunotherapy...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2017.1029

    authors: Blumenthal GM,Zhang L,Zhang H,Kazandjian D,Khozin S,Tang S,Goldberg K,Sridhara R,Keegan P,Pazdur R

    更新日期:2017-08-10 00:00:00

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

    abstract:Importance:Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective:To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated pro...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0910

    authors: Chen EX,Jonker DJ,Loree JM,Kennecke HF,Berry SR,Couture F,Ahmad CE,Goffin JR,Kavan P,Harb M,Colwell B,Samimi S,Samson B,Abbas T,Aucoin N,Aubin F,Koski SL,Wei AC,Magoski NM,Tu D,O'Callaghan CJ

    更新日期:2020-06-01 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00